The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Nasdaq1d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below ... patients receiving the highest dose of amycretin experienced a 22% ...
Nanexa AB: Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study
Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide. NEX-22 is a new promising treatmen ...
Healthline23d
All About Victoza
Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.
Nanexa AB: Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22
Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide. The ongoing Phase ...
Mint1d
Mint Explainer: How big is the weight-loss drug market in India
It’s not just for the celebrities anymore. The ‘miracle’ weight loss drug race has arrived in India with the launch of American drugmaker Eli Lilly’s Mounjaro last week. Priced at ...